Ozempic and Wegovy would no longer be covered by the state’s health insurance for low-income people under the governor’s ...

Weight loss drugs like semaglutide could add £4.5 billion to the UK economy annually, boosting productivity and reducing ...

European governments are examining whether US President Donald Trump can force them to pay more for prescription medicines, ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments ...

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...

The Ozempic maker and its peers are setting their sights on oral obesity medications to diversify their portfolios and remain ...

The executive order would require other countries to pay more for medications so that Americans could pay less. But experts ...

Eli Lilly is pumping iron in the GLP-1 prescription ring, gaining muscle with a 52.4% market share and a beefy $1,100 target.

Novo Nordisk A/S is partnering with US biotech Septerna Inc. on the development of oral pills for obesity in a deal ...

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

Shoppers in the United States have been worried about the impact tariffs might have on their groceries and cost of living, but finally there is a bit of good news—thanks to a new executive order ...